3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
4
Neoplasms
3
Sarcoma
2
Lymphoma, Follicular
2
Lymphoma
2
Glioblastoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Thrombosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumothorax
1
Pituitary Neoplasms
1
Philadelphia Chromosome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Opioid-Related Disorders
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metastatic Castration-resistant Prostate Cancer
1
Meningioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Nivolumab
2
radium Ra 223 dichloride
1
poly ICLC
1
fludarabine phosphate
1
fludarabine
1
darolutamide
1
cabozantinib
1
bempegaldesleukin
1
Radium-223
1
Radiosurgery
1
Pluvicto
1
Cyclophosphamide
1
Blood Specimen Collection
1
Abiraterone Acetate
1
177Lu-EB-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Metastatic Castration-resistant Prostate Cancer
×
Blood Specimen Collection
×
Clear all
NCT06492122
2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1
Recruiting
50 enrolled